41292-66-4

Usage

Uses

Since the specific applications of 1H-Benzimidazol-5-ol,2-methyl-(9CI) are not provided in the materials, it is not possible to list its uses based on the given information. However, as a part of the Benzimidazole group, 1H-Benzimidazol-5-ol,2-methyl-(9CI) may have potential applications in various industries, such as pharmaceuticals, due to its potential pharmacological actions. Further research and documentation would be required to confirm its specific uses and application reasons.

Upstream product

• 610-81-1 4-hydroxy-2-nitroaniline 
• 64-19-7 acetic acid 
• 4887-81-4 5⁽⁶⁾-methoxy 2-methyl benzimidazole 
• 78-39-7 Triethyl orthoacetate 
• 615-72-5 3,4-diaminophenol 
• 75-36-5 acetyl chloride 

Downstream Products

• 124841-32-3 4-chloro-5-hydroxy-2-methyl-1H-benzo[d]imidazole 
• 127025-81-4 2-methyl-5-hydroxy-4-nitrobenzimidazole 
• 128728-08-5 4-(5-Hydroxy-2-methyl-1H-benzoimidazol-4-ylazo)-benzenesulfonic acid 
• 128728-06-3 2-Methyl-4-phenylazo-1H-benzoimidazol-5-ol 
• 128728-07-4 2-Methyl-4-(4-nitro-phenylazo)-1H-benzoimidazol-5-ol 
• 101018-70-6 2-methyl-4-(dimethylaminomethyl)-5-hydroxybenzimidazole 
• 101018-69-3 2-methyl-4-(morpholinomethyl)-5-hydroxybenzimidazole 

Relevant academic research and scientific papers

A facile one-pot synthesis of benzimidazoles from 2-nitroanilines by reductive cyclization

A facile one-pot process to prepare benzimidazole derivatives is described. Reductive cyclization of a serial of 2-nitroanilines with orthoesters in the presence of Pd/C in methanol at room temperature, which is promoted by a catalytic amount of acetic acid, affords the corresponding benzimidazole derivatives in high yields.

QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS

The invention relates to the use of compounds of the formula I: wherein ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which optionally may contain 1-3 heteroatoms selected independently from O, N and S; Z is -O-, -NH-, -S-, -CH2- or a direct bond; n is 0-5; m is 0-3; R represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, C1-3alkoxy, C1-3alkylsulphanyl, -NRR (wherein R and R, which may be the same or different, each represents hydrogen or C1-3alkyl), or RX- (wherein X and R are as defined herein; R represents hydrogen, oxo, halogeno, hydroxy, C1-4alkoxy, C1-4alkyl, C1-4alkoxymethyl, C1-4alkanoyl, C1-4haloalkyl, cyano, amino, C2-5alkenyl, C2-5alkynyl, C1-3alkanoyloxy, nitro, C1-4alkanoylamino, C1-4alkoxycarbonyl, C1-4alkylsulphanyl, C1-4alkylsulphinyl, C1-4alkylsulphonyl, carbamoyl, N-C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, aminosulphonyl, N-C1-4alkylaminosulphonyl, N,N-di(C1-4alkyl)aminosulphonyl, N-(C1-4alkylsulphonyl)amino, N-(C1-4alkylsulphonyl)-N-(C1-4alkyl)amino, N,N-di(C1-4alkylsulphonyl)amino, a C3-7alkylene chain joined to two ring C carbon atoms, C1-4alkanoylaminoC1-4alkyl, carboxy or a group RX (wherein X and R are as defined herein); and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula I. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

Rapid one-pot preparation of 2-substituted benzimidazoles from 2-nitroanilines using microwave conditions

A high yielding one-pot procedure for the generation of 2-substituted benzimidazoles directly from 2-nitroanilines by in situ reduction and cyclization using a microwave procedure is described.

Design, synthesis, and in vitro biological activity of benzimidazole based Factor Xa inhibitors

Inhibitors based on the benzimidazole scaffold showed subnanomolar potency against Factor Xa with 500-1000-fold selectivity against thrombin and 50-100-fold selectivity against trypsin. The 2-substituent on the benzimidazole ring had a strong impact on th